UNSPSC 51281677: Tobramycin sulfate

This classification denotes an aminoglycoside antibiotic with the molecular formula 2C18H37N5O9.5H2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier HJT0RXD7JK, chemically known as tobramycin, free base but more generally known as tobramycin sulfate, which bears US NIH Compound Identifier 5496. European Medicines Agency schedules Tobramycin sulfate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04896MIG.

Most nations, for tariff and trade purposes, schedule tobramycin sulfate under HS 29419000 and SITC 54139. Tobramycin sulfate bears US NLM identifiers UMLS ID C0701392 and NCI Concept Code C893. SMILES: As of Q4 2014, TOBRAMYCIN SULFATE remains US FDA's Preferred Term for this commodity.

UNSPSC 51281677 Tobramycin sulfate is a Commodity code representing pharmaceutical active ingredients and finished pharmaceuticals procured by state and local health departments and special-purpose health agencies. The recent opportunities in the dataset show a significant mismatch: the two posted records tag pharmaceutical warehouse and emergency-medicine procurements (Doxycycline Hyclate, Ciprofloxacin Hydrochloride, and Naloxone) under this code, but neither solicitation specifically names Tobramycin sulfate or antibiotic injectables as the commodity being acquired. State and local buyers under this code are primarily state health departments and county health authorities purchasing pharmaceutical inventory to support emergency preparedness, disease treatment programs, and community health initiatives. The Illinois Department of Public Health and Seminole County, Florida represent the issuing bodies visible in recent activity, though the code shows limited direct procurement signals specific to Tobramycin itself.

Activity under UNSPSC 51281677 appears concentrated in the Southeast and Midwest. Recent awards include the Illinois Department of Public Health's $2,999,999.11 piggyback contract through the MMCAP Infuse consortium to Chartwell Rx LLC for antibiotic pharmaceuticals (awarded August 28, 2026, via IFB) and Seminole County, Florida's procurement of 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually (IFB released June 30, 2026, with response due July 26, 2023). The Illinois award demonstrates three-year contract terms with renewal options and the use of cooperative purchasing vehicles to aggregate pharmaceutical demand. No explicit set-aside designations or minority or veteran business preferences appear in the posted records. The code shows little recent activity with strong Tobramycin-specific signals; vendors should verify state and local pharmaceutical formulary requirements and cooperative-purchasing vehicle eligibility before pursuing.